company background image
SUNP

Sun Pharmaceutical IndustriesNSEI:SUNPHARMA Stock Report

Last Price

₹808.75

Market Cap

₹1.9t

7D

-5.9%

1Y

40.6%

Updated

23 Jan, 2022

Data

Company Financials +
SUNPHARMA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends4/6

SUNPHARMA Stock Overview

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally.

Sun Pharmaceutical Industries Competitors

Dr. Reddy's Laboratories

BSE:500124

₹746.4b

Cipla

NSEI:CIPLA

₹699.9b

Alkem Laboratories

BSE:539523

₹425.1b

Cadila Healthcare

NSEI:CADILAHC

₹420.1b

Price History & Performance

Summary of all time highs, changes and price drops for Sun Pharmaceutical Industries
Historical stock prices
Current Share Price₹808.75
52 Week High₹871.00
52 Week Low₹550.40
Beta0.48
1 Month Change2.97%
3 Month Change-0.55%
1 Year Change40.60%
3 Year Change91.47%
5 Year Change26.27%
Change since IPO39,683.11%

Recent News & Updates

Jan 19
Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Dec 27
Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Sun Pharmaceutical...

Nov 04
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

SUNPHARMAIN PharmaceuticalsIN Market
7D-5.9%-4.5%-3.4%
1Y40.6%8.8%32.6%

Return vs Industry: SUNPHARMA exceeded the Indian Pharmaceuticals industry which returned 8.8% over the past year.

Return vs Market: SUNPHARMA exceeded the Indian Market which returned 32.6% over the past year.

Price Volatility

Is SUNPHARMA's price volatile compared to industry and market?
SUNPHARMA volatility
SUNPHARMA Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.8%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.0%

Stable Share Price: SUNPHARMA is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: SUNPHARMA's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198337,000Dilip Shanghvihttps://www.sunpharma.com

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products.

Sun Pharmaceutical Industries Fundamentals Summary

How do Sun Pharmaceutical Industries's earnings and revenue compare to its market cap?
SUNPHARMA fundamental statistics
Market Cap₹1.94t
Earnings (TTM)₹62.38b
Revenue (TTM)₹367.04b

31.1x

P/E Ratio

5.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SUNPHARMA income statement (TTM)
Revenue₹367.04b
Cost of Revenue₹102.74b
Gross Profit₹264.31b
Expenses₹201.93b
Earnings₹62.38b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jan 31, 2022

Earnings per share (EPS)26.00
Gross Margin72.01%
Net Profit Margin16.99%
Debt/Equity Ratio3.4%

How did SUNPHARMA perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

30%

Payout Ratio

Valuation

Is Sun Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

31.11x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SUNPHARMA (₹808.75) is trading above our estimate of fair value (₹697.2)

Significantly Below Fair Value: SUNPHARMA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SUNPHARMA is poor value based on its PE Ratio (31.1x) compared to the Indian Pharmaceuticals industry average (25.7x).

PE vs Market: SUNPHARMA is poor value based on its PE Ratio (31.1x) compared to the Indian market (23x).


Price to Earnings Growth Ratio

PEG Ratio: SUNPHARMA is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: SUNPHARMA is overvalued based on its PB Ratio (3.9x) compared to the IN Pharmaceuticals industry average (3.1x).


Future Growth

How is Sun Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 31 analysts?

15.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUNPHARMA's forecast earnings growth (15.8% per year) is above the savings rate (6.7%).

Earnings vs Market: SUNPHARMA's earnings (15.8% per year) are forecast to grow slower than the Indian market (21.3% per year).

High Growth Earnings: SUNPHARMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: SUNPHARMA's revenue (9.9% per year) is forecast to grow slower than the Indian market (12.9% per year).

High Growth Revenue: SUNPHARMA's revenue (9.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SUNPHARMA's Return on Equity is forecast to be low in 3 years time (14.8%).


Past Performance

How has Sun Pharmaceutical Industries performed over the past 5 years?

-10.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUNPHARMA has high quality earnings.

Growing Profit Margin: SUNPHARMA's current net profit margins (17%) are higher than last year (4.5%).


Past Earnings Growth Analysis

Earnings Trend: SUNPHARMA's earnings have declined by 10.4% per year over the past 5 years.

Accelerating Growth: SUNPHARMA's earnings growth over the past year (324.2%) exceeds its 5-year average (-10.4% per year).

Earnings vs Industry: SUNPHARMA earnings growth over the past year (324.2%) exceeded the Pharmaceuticals industry 29.7%.


Return on Equity

High ROE: SUNPHARMA's Return on Equity (11.9%) is considered low.


Financial Health

How is Sun Pharmaceutical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: SUNPHARMA's short term assets (₹320.8B) exceed its short term liabilities (₹148.1B).

Long Term Liabilities: SUNPHARMA's short term assets (₹320.8B) exceed its long term liabilities (₹17.8B).


Debt to Equity History and Analysis

Debt Level: SUNPHARMA has more cash than its total debt.

Reducing Debt: SUNPHARMA's debt to equity ratio has reduced from 20.3% to 3.4% over the past 5 years.

Debt Coverage: SUNPHARMA's debt is well covered by operating cash flow (462.7%).

Interest Coverage: SUNPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Sun Pharmaceutical Industries's current dividend yield, its reliability and sustainability?

0.93%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: SUNPHARMA's dividend (0.93%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).

High Dividend: SUNPHARMA's dividend (0.93%) is low compared to the top 25% of dividend payers in the Indian market (1.34%).


Stability and Growth of Payments

Stable Dividend: SUNPHARMA's dividend payments have been volatile in the past 10 years.

Growing Dividend: SUNPHARMA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.8%), SUNPHARMA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: SUNPHARMA's dividends in 3 years are forecast to be well covered by earnings (18.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure


CEO

Dilip Shanghvi (66 yo)

no data

Tenure

₹46,052,839

Compensation

Mr. Dilip Shantilal Shanghvi has been the Chairman of Sun Pharma Advanced Research Company Limited since March 1, 2012 and served as its Managing Director since March 1, 2012 until May 25, 2021 . Mr. Shang...


CEO Compensation Analysis

Compensation vs Market: Dilip's total compensation ($USD619.65K) is below average for companies of similar size in the Indian market ($USD1.20M).

Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: SUNPHARMA's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SUNPHARMA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sun Pharmaceutical Industries Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Sun Pharmaceutical Industries Limited
  • Ticker: SUNPHARMA
  • Exchange: NSEI
  • Founded: 1983
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹1.940t
  • Shares outstanding: 2.40b
  • Website: https://www.sunpharma.com

Number of Employees


Location

  • Sun Pharmaceutical Industries Limited
  • Sun House
  • Plot No. 201 B/1
  • Mumbai
  • Maharashtra
  • 400063
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 12:05
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.